L3VLUP
ProSign in

EDIT in the 13F filings

Editas Medicine Inc · CUSIP 28106W103

Sector · Pharmaceuticals and biotechnologyTheme · Biological productsTheme · Healthcare: biopharma and medtech· L3VLUP-defined
Quarter
Q2 2026Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022
Quarter end
31 Mar 2023
the date the book describes
Filed
15 May 2023
latest of these filings; the earliest 17 Apr 2023
Managers listing it
3
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q4 2022 and Q1 2023; 3 listed it in both
Shares listed
2,785,726
combined, among listed positions
Reported value
$20m
combined, at the quarter end

Managers listing EDIT in Q1 2023

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q4 2022, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

3 of 3 holders

ActionFiling
Woodline Partners LP2,646,620$19m0.26%Added+567,87215 May 2023 (the filing on sec.gov)
Caxton Associates LLP107,708$781k0.12%Added+93,37515 May 2023 (the filing on sec.gov)
PDT Partners LLC31,398$228kunder 0.1%Trimmed-78,20215 May 2023 (the filing on sec.gov)

Largest increases and reductions, by shares

Q4 2022 to Q1 2023, among managers that listed it in both quarters or opened it.

Increases

Reductions

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (0)

No new position among listed positions.

Exited (1)

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
3 in Q1 2023 to 1 in Q2 2026

Tracked managers listing it, at least.

02468201620172018201920202021202220232024
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
EDIT by quarter
QuarterHoldersReported valueBuyersSellers
Q1 20163$84mn.a.n.a.
Q2 20163$49mn.a.n.a.
Q3 20163$27mn.a.n.a.
Q4 20162$33mn.a.n.a.
Q1 20174$85mn.a.n.a.
Q2 20174$69mn.a.n.a.
Q3 20175$103mn.a.n.a.
Q4 20175$159mn.a.n.a.
Q1 20187$180mn.a.n.a.
Q2 20185$199mn.a.n.a.
Q3 20185$190mn.a.n.a.
Q4 20184$136mn.a.n.a.
Q1 20194$182mn.a.n.a.
Q2 20194$189mn.a.n.a.
Q3 20194$171mn.a.n.a.
Q4 20196$266mn.a.n.a.
Q1 20207$172mn.a.n.a.
Q2 20207$361mn.a.n.a.
Q3 20205$378mn.a.n.a.
Q4 20206$969mn.a.n.a.
Q1 20217$498mn.a.n.a.
Q2 20216$540mn.a.n.a.
Q3 20215$349mn.a.n.a.
Q4 20215$178mn.a.n.a.
Q1 20226$86mn.a.n.a.
Q2 20226$41mn.a.n.a.
Q3 20225$42mn.a.n.a.
Q4 20225$29mn.a.n.a.
Q1 20233$20mn.a.n.a.
Q2 20234$47mn.a.n.a.
Q3 20234$44mn.a.n.a.
Q4 20233$21m12
Q1 20242$7.0m12
Q2 20243$6.3m30
Q3 20242$3.5m02
Q2 20261$12m149

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

EDIT and GILD →EDIT and AMGN →EDIT and ARGX →Choose a stock to compare with EDIT →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own EDIT, latest filings →Back to the 13F Explorer →